Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Cash & Equivalents (2016 - 2025)

Catalyst Pharmaceuticals' Cash & Equivalents history spans 16 years, with the latest figure at $709.2 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 37.02% year-over-year to $709.2 million; the TTM value through Dec 2025 reached $709.2 million, up 37.02%, while the annual FY2025 figure was $709.2 million, 37.02% up from the prior year.
  • Cash & Equivalents reached $709.2 million in Q4 2025 per CPRX's latest filing, up from $689.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $709.2 million in Q4 2025 to a low of $121.0 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $319.8 million, with a median of $233.5 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: tumbled 53.87% in 2023, then surged 276.03% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $171.4 million in 2021, then surged by 74.05% to $298.4 million in 2022, then crashed by 53.87% to $137.6 million in 2023, then soared by 276.03% to $517.6 million in 2024, then skyrocketed by 37.02% to $709.2 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Cash & Equivalents are $709.2 million (Q4 2025), $689.9 million (Q3 2025), and $652.8 million (Q2 2025).